Binds Antigen Characterized By Name Or Molecular Weight (e.g., Cea, Nca, Cc Glycoprotein, Melanoma Gp 150 Antigen, Etc.) Patents (Class 530/388.85)
-
Patent number: 8058406Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody.Type: GrantFiled: July 9, 2009Date of Patent: November 15, 2011Assignee: Biogen Idec MA Inc.Inventors: Sha Mi, R. Blake Pepinsky, Christilyn Graff
-
Patent number: 8053563Abstract: The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e.g. inhibit the growth and/or inducing apoptosis of cells, in particular cancer cells. The invention also relates to pharmaceutical compositions comprising said antibodies and uses said antibodies and/or pharmaceutical compositions for treatment of a disease wherein inhibition of cell growth, cell differentiation, remodelling of extracellular matrix, metastasis and/or induction of cell death due to apoptosis is a prerequisite for successful curing. An antibody of the invention is capable of inhibiting biological function of YKL-40 in the above mentioned processes by binding to a specific epitope on YKL-40.Type: GrantFiled: February 16, 2006Date of Patent: November 8, 2011Assignee: BIO-Y A/SInventors: Richard Bonnichsen, Paul Price
-
Publication number: 20110223182Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung.Type: ApplicationFiled: September 16, 2009Publication date: September 15, 2011Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Rita Mitnacht-Kraus
-
Patent number: 8013128Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: March 4, 2009Date of Patent: September 6, 2011Assignee: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
-
Patent number: 7994287Abstract: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.Type: GrantFiled: June 23, 2008Date of Patent: August 9, 2011Assignee: Millennium Pharmaceuticals, Inc.Inventors: Shixin Qin, Nasim Kassam, Walter Newman
-
Patent number: 7977462Abstract: The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: GrantFiled: April 18, 2008Date of Patent: July 12, 2011Assignee: Cell Signaling Technology, Inc.Inventors: Peter Hornbeck, Ailan Guo, Ting-Lei Gu, Klarisa Rikova, Albrecht Moritz, Charles Farnsworth, Matthew Stokes, Jian Yu, Erik Spek, Yu Li, Anthony Possemato, Jessica Cherry, Valerie Goss, Jeffrey Mitchell, John Rush, Corinne Michaud
-
Patent number: 7973138Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.Type: GrantFiled: September 25, 2008Date of Patent: July 5, 2011Assignee: Genentech, Inc.Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
-
Patent number: 7968688Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.Type: GrantFiled: January 8, 2009Date of Patent: June 28, 2011Assignee: University of RochesterInventors: Maurice Zauderer, Elizabeth E. Evans
-
Patent number: 7968687Abstract: This invention relates to CD 19 binding agents and methods of using such CD 19 binding agents for treating disease.Type: GrantFiled: October 17, 2008Date of Patent: June 28, 2011Assignee: Seattle Genetics, Inc.Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
-
Patent number: 7947812Abstract: The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.Type: GrantFiled: March 15, 2004Date of Patent: May 24, 2011Assignee: Patrys LimitedInventors: Hans-Konrad Mueller-Hermelink, Heinz Peter Vollmers
-
Patent number: 7932055Abstract: Soluble versions of heterodimeric receptors, e.g., CD94/NKG2 receptors, and methods of producing and using such constructs, are described. The constructs comprise soluble fragments of, each receptor monomer, and some constructs further comprise at least one immunoglobulin Fc domain. Exemplary constructs are those wherein (1) each soluble fragment is linked to an immunoglobulin Fc domain, which are then allowed to dimerize, (2) each soluble fragment is linked to an immunoglobulin Fc domain mutated to promote forced dimerization with the correct counterpart, and (3) single-chain constructs where the monomeric receptor fragments are linked, and the C-terminal fragment is linked to an Fc domain.Type: GrantFiled: June 22, 2007Date of Patent: April 26, 2011Assignee: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Søren Berg Padkær, Birgitte Nissen Friedrichsen, Inga Sig Nielsen Nørby
-
Patent number: 7919314Abstract: Provided is a use of a recombinant chimaeric protein as an immunogen in a process for producing a monoclonal antibody, wherein the recombinant chimaeric protein is assembled into a virus-like particles, and includes a foreign protein or peptide or a fragment thereof.Type: GrantFiled: October 12, 2007Date of Patent: April 5, 2011Assignee: Biotechnologijos InstitutasInventors: Aurelija Zvirbliene, Alma Gedvilaite, Rainer Ulrich, Kestutis Sasnauskas
-
Patent number: 7897139Abstract: The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of PTHrP, its isoforms or PTHrP signalling. The present invention is also directed to methods of inhibiting the PTHrP1-173 isoform through antagonists thereof, including monoclonal antibodies and siRNA directed there against. The invention may be applicable to many disease states, including but not limited to several types of cancer (such as breast, lung, prostate, melanoma and squamous) expressing PTHrP and its isoforms, alone or in combination with other therapeutic agents.Type: GrantFiled: August 17, 2007Date of Patent: March 1, 2011Assignee: Biochrom Pharma, Inc.Inventors: Richard Kremer, Dao Chao Huang
-
Patent number: 7892554Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: June 1, 2007Date of Patent: February 22, 2011Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Patent number: 7892547Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: April 9, 2009Date of Patent: February 22, 2011Assignee: Immunomedics, Inc.Inventors: William J. McBride, Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen
-
Patent number: 7888485Abstract: The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an effective amount of the antibodies described herein. The present invention also provides for methods of making the neutralizing antibodies described herein.Type: GrantFiled: March 26, 2004Date of Patent: February 15, 2011Assignee: Georgetown UniversityInventors: J. Yun Tso, Anton Wellstein, Debra Chao
-
Patent number: 7887808Abstract: Naturally-occurring variants of human Rgr oncogene protein, in particular, abnormally truncated variants found in T cell malignancies, as well as the human Rgr protein are encompassed by the present invention. Also included are antibodies thereto and nucleic acid molecules encoding human Rgr protein and naturally-occurring variants thereof. The present invention further provides methods for diagnosing and treating T cell malignancies associated with abnormally truncated transcripts of human rgr oncogene and/or abnormal truncation of human Rgr protein.Type: GrantFiled: April 25, 2008Date of Patent: February 15, 2011Assignee: New York UniversityInventors: Angel Pellicer, Peter Leonardi, Giorgio Inghirami
-
Patent number: 7883702Abstract: The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific anti-mortalin antibody, was injected into a tumor of a nude mouse, tumor growth was suppressed or the tumor shrank compared with the case of a control. In accordance with the present invention, the use of a specific anti-mortalin antibody (K antibody) for tumor therapies and the use of such antibody as a carrier molecule for transportation of immunotoxicin and the like into cells are provided. It has been shown that mortalin can be a target for cancer therapies. In accordance with the present invention, a novel and effective anticancer agent is provided. In addition, an anti-mortalin antibody that is internalized by cells is developed.Type: GrantFiled: August 25, 2005Date of Patent: February 8, 2011Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Renu Wadhwa, Kazunari Taira, Sunil Kaul
-
Patent number: 7879984Abstract: A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human lymphoma. The antibody or antigen-binding fragment thereof is useful in a therapeutic method for treating a CD20-mediated disease or condition, such as for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases.Type: GrantFiled: July 31, 2008Date of Patent: February 1, 2011Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
-
Patent number: 7879990Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.Type: GrantFiled: January 8, 2009Date of Patent: February 1, 2011Assignee: University of RochesterInventors: Maurice Zauderer, Elizabeth E. Evans
-
Patent number: 7872104Abstract: This invention concerns an antibody which binds with high affinity to human single-chain intact, i.e. not internally cleaved, mature and/or zymogen forms of prostate specific antigen (SCINT PSA). The antibody does not bind to a nicked PSA (PSA-N), wherein said PSA-N has been formed by internal peptide bond cleavage(s) of SCINT PSA resulting in two-chain or multi-chain PSA. This invention further concerns an immunoassay and a method for differentiating patients with cancer of the prostate (PCa) from patients with benign prostatic hyperplasia (BPH) and/or healthy male subjects without PCa, patients with aggressive PCa from patients with indolent PCa and/or patients with clinically localized and/or organ confined PCa from patients with extraprostatic extension of PCa and/or PCa with metastatic spread to lymph nodes or bone marrow using said antibody.Type: GrantFiled: September 26, 2001Date of Patent: January 18, 2011Assignee: Arctic Partners Oy ABInventors: Kim Pettersson, Hans Lilja, Timo Lövgren, Pauliina Niemelä
-
Patent number: 7871762Abstract: The invention provides methods for detecting the presence or absence of invasive trophoblast cells. In addition, the invention provides methods for distinguishing quiescent trophoblast diseases from invasive trophoblast diseases and methods for monitoring progression of quiescent trophoblast diseases. The invention provides methods for detecting the presence or absence of germ cell tumors.Type: GrantFiled: July 9, 2003Date of Patent: January 18, 2011Assignee: STC.UNMInventor: Laurence A. Cole
-
Patent number: 7867725Abstract: The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis.Type: GrantFiled: October 30, 2007Date of Patent: January 11, 2011Assignees: Maine Medical Center, University of Maine System BoardInventors: Lucy Liaw, Ah-Kau Ng
-
Patent number: 7862817Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.Type: GrantFiled: January 27, 2005Date of Patent: January 4, 2011Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
-
Patent number: 7858760Abstract: A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24P4C12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and/or therapeutic target for prostate and other cancers.Type: GrantFiled: September 7, 2004Date of Patent: December 28, 2010Assignee: Agensys, Inc.Inventors: Daniel E. H. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas Saffran
-
Publication number: 20100322950Abstract: Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5 kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5 kD and antibodies specific for OPN-5 kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5 kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5 kD.Type: ApplicationFiled: August 30, 2010Publication date: December 23, 2010Inventors: VIVIAN TAKAFUJI, XIN WEI WANG, EDWARD J. UNSWORTH, PAUL K. GOLDSMITH
-
Patent number: 7850966Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains.Type: GrantFiled: September 24, 2008Date of Patent: December 14, 2010Assignee: Genentech, Inc.Inventors: Henry B. Lowman, Resi B. Gerstner, Paul J. Carter
-
Publication number: 20100310559Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.Type: ApplicationFiled: June 28, 2010Publication date: December 9, 2010Applicant: Neogenix Oncology, Inc.Inventors: Myron Arlen, J. Andrew Bristol, Ariel C. Hollinshead, Kwong Y. Tsang
-
Publication number: 20100297138Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.Type: ApplicationFiled: December 8, 2006Publication date: November 25, 2010Inventors: Cynthia A. Vistica, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
-
Patent number: 7833528Abstract: Embodiments of the invention relate to a method for treating target cells, tissues or pathogens in a subject, comprising administering a non-covalently bound complex which comprises a multispecific targeting protein and a hapten-enzyme covalent conjugate, followed by administration of a prodrug that is converted to an active drug by the enzyme. Other embodiments of the invention further relate to kits comprising the non-covalently bound complex or the components to prepare the complex.Type: GrantFiled: October 27, 2006Date of Patent: November 16, 2010Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Serengulam V. Govindan, Hans J. Hansen
-
Patent number: 7834155Abstract: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.Type: GrantFiled: August 29, 2005Date of Patent: November 16, 2010Assignee: Immunogen Inc.Inventors: Gillian Payne, Philip Chun, Daniel J. Tavares
-
Patent number: 7820164Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.Type: GrantFiled: January 12, 2010Date of Patent: October 26, 2010Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg
-
Publication number: 20100260769Abstract: The invention relates to novel binding molecules that specifically bind endosialin (TEM-1) including antibodies, such as monoclonal antibodies, or antigen-binding portions of antibodies, and methods and compositions comprising such binding molecules.Type: ApplicationFiled: April 8, 2010Publication date: October 14, 2010Applicant: MORPHOTEK, INC.Inventors: Philip M. Sass, Brad Kline, Nicholas Nicolaides, Luigi Grasso, Stephen Harley
-
Patent number: 7812133Abstract: The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies.Type: GrantFiled: December 15, 2006Date of Patent: October 12, 2010Assignee: Genentech, IncInventor: Flavius Martin
-
Patent number: 7799900Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.Type: GrantFiled: June 7, 2005Date of Patent: September 21, 2010Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Andrew C. Chan, Craig W. Crowley, Henry B. Lowman, Gerald R. Nakamura, Leonard G. Presta
-
Patent number: 7790165Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: June 8, 2007Date of Patent: September 7, 2010Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
-
Patent number: 7786266Abstract: The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides methods and pharmaceutical compositions that comprise anti-DSC2 antibody as an active ingredient for damaging DSC2-expressing cells via the effector function of the antibody.Type: GrantFiled: May 11, 2006Date of Patent: August 31, 2010Assignee: Oncotherapy Science, Inc.Inventors: Shuichi Nakatsuru, Takashi Iwamoto, Megumi Yoshikawa
-
Patent number: 7785812Abstract: Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP-?. The disclosed compositions include MRP-? nucleic acids, including probes and antisense oligonucleotides, MRP-? polypeptides and antibodies, MRP-? expressing host cells, and non-human mammals transgenic or nullizygous for MRP-?. The disclosed methods include methods for attenuating aberrant MRP-? gene expression, protein production and/or protein function. In addition, methods are disclosed for identifying and using a modulator, such as an inhibitor, of MRP-?. Preferably, the modulator is a small molecule.Type: GrantFiled: April 11, 2005Date of Patent: August 31, 2010Assignee: Millennium Pharmaceuticals, Inc.Inventor: Andrew W. Shyjan
-
Patent number: 7777010Abstract: The invention provides a method for selecting at least one member from a library of proteinaceous molecules by providing at least one cell and/or a functional equivalent thereof, with at least part of the library under conditions that allow binding of any such member to an epitope in and/or on the cells and/or the functional equivalent thereof, removing unbound proteinaceous molecules and selecting the at least one member, wherein the library includes at least one mutant of a proteinaceous molecule capable of binding to the epitope.Type: GrantFiled: June 28, 2002Date of Patent: August 17, 2010Assignee: Crucell Holland B.V.Inventor: Ton Logtenberg
-
Patent number: 7776330Abstract: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.Type: GrantFiled: September 25, 2007Date of Patent: August 17, 2010Assignee: City of HopeInventors: Paul J. Yazaki, Mark A. Sherman, John E. Shively, Andrew A. Raubitschek, Anna M. Wu
-
Publication number: 20100202964Abstract: Provided herein are methods that use liver targeting domains of colon cancer, such as for example PA28alpha, HNRNPA1, and/or KIAA1407, and the polynucleotides that encode them, for the prognosis, diagnosis, detection, staging and/or prediction of survival rates in individuals with colon cancer, whether the cancer has metastasized or not, as well as for imaging purposes and design of diagnostic and/or therapeutic methods.Type: ApplicationFiled: April 5, 2006Publication date: August 12, 2010Applicant: Georgetown UniversityInventor: Anton Wellstein
-
Patent number: 7772375Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: GrantFiled: December 11, 2006Date of Patent: August 10, 2010Assignee: AC Immune S.A.Inventors: Ruth Greferath, David Hickman, Andreas Muhs, Andrea Pfeifer, Claude Nicolau
-
Patent number: 7772373Abstract: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.Type: GrantFiled: October 5, 2007Date of Patent: August 10, 2010Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 7763249Abstract: A human anti-amyloid ? peptide (hereinafter referred to as “A?”) antibody that binds to A? to thereby inhibit aggregation of A? molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, comprising a variable region of a human-derived anti-A? antibody, strongly reacts with A? to thereby inhibit its aggregation and hence may be used as a medicament for the prophylaxis and treatment of Alzheimer dementia.Type: GrantFiled: April 21, 2005Date of Patent: July 27, 2010Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Kazuhisa Sugimura, Toshihiro Nakashima
-
Patent number: 7754211Abstract: Novel immunotoxins and methods of treating neoplastic diseases are provided. More specifically, immunotoxins comprised conjugation of a c-erbB-2 targeting moiety and a cell growth modulator are provided. These immunotoxins specifically and selectively kill tumor cells that over-express the c-erbB-2 protein. The novel immunotoxins would be useful in treating human mammary carcinomas, human ovarian carcinomas, lung carcinomas, gastric tumors, salivary gland adenocarcinomas, and colon adenocarcinomas.Type: GrantFiled: October 13, 2004Date of Patent: July 13, 2010Assignee: Research Development FoundationInventors: Michael Rosenblum, Laura K. Shawver
-
Patent number: 7750125Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.Type: GrantFiled: August 17, 2007Date of Patent: July 6, 2010Assignee: University of RochesterInventors: Maurice Zauderer, Elizabeth E. Evans
-
Patent number: 7744884Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.Type: GrantFiled: December 19, 2007Date of Patent: June 29, 2010Assignee: NovImmune S.A.Inventor: Greg Elson
-
Patent number: 7744877Abstract: Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.Type: GrantFiled: September 11, 2002Date of Patent: June 29, 2010Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
-
Patent number: 7741447Abstract: The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer based on the expression of the human oculospanin gene as a marker and a pharmaceutical composition containing an antibody capable of specifically recognizing human oculospanin and having cytotoxic activity against cancer cells.Type: GrantFiled: October 15, 2007Date of Patent: June 22, 2010Assignee: Sankyo Co., Ltd.Inventors: Kimihasa Ichikawa, Shu Takahashi, Toshinori Agatsuma, Keisuke Fukuchi, Takehiro Hirai
-
Patent number: 7740847Abstract: The present invention provides humanized anti-CD20 antibodies comprising a human IgG1 Fc region comprising an isoleucine at position 247 and a glutamine at position 339 as well as nucleic acids encoding the antibodies and methods of using the antibodies for treating lymphoma. Furthermore, the invention provides compositions comprising the antibodies and methods of producing them.Type: GrantFiled: July 18, 2005Date of Patent: June 22, 2010Assignee: Applied Molecular Evolution, Inc.Inventors: Barrett Allan, Weidong Jiang, Ying Tang, Jeffry Dean Watkins